Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/344128
Title: Design Synthesis and Biological Evaluation of Small Molecules targeting Histone Deacetylase HDAC as Anti Cancer Agents
Researcher: Gediya, Piyush
Guide(s): Ghate, Manjunath
Keywords: cancer
Clinical Pre Clinical and Health
Histone deacetylase
pharmacokinetics
Pharmacology and Toxicology
University: Nirma University
Completed Date: 2021
Abstract: Histone deacetylase (HDAC) enzymes are one of the best-characterized epigenetic targets; the aberrant activity of one or more of the 11 zinc-dependent HDAC isoforms has been associated with many different cancers, as well as several other diseases. Some HDAC inhibitors have been proven efficacious in treating cancer; three are FDA approved for treating cutaneous T-cell lymphoma or multiple myeloma. Animal models of other diseases have shown that HDAC inhibitors have potential as therapeutic agents. However, the clinical use of HDAC inhibitors is currently limited by toxicity and side effects, amongst other problems, possibly arising because the inhibitors are not isoform-selective. This thesis focuses on attempts to synthesize novel HDAC inhibitors with increased isoform selectivity. newlineTo identify the core scaffold, pharmacophore modeling was carried out with the aid of the GASP module of Sybyl X, which gave four feature pharmacophores which consisted of two hydrophobic features, one acceptor atom, and one donor atom of the receptor protein. Further, this model was validated by GH score analysis. According to the generated pharmacophore model and literature survey, HDAC inhibitors consist of a) Cap group, b) linker group, and c) Zinc binding group. Based on this data, we have designed some fused heterocyclic compounds. Docking studies and in-silico pharmacokinetics and toxicities were predicted for the best-ranked designed compounds. Two different series of compounds with two linker groups were designed, and their synthetic routes were proposed. In-silico ADMET property of the designed compounds was evaluated and was found to be non-toxic. newlineBased on the results of docking studies, in-silico pharmacokinetics prediction, and synthetic feasibility, total 16 molecules were synthesized in series I, and 16 molecules were synthesized in series II. newlineA series of designed molecules were synthesized and tested for inhibition of HDAC isoforms. Compound 69h and 74n were found to be potent molecules in the cell-based
Pagination: 
URI: http://hdl.handle.net/10603/344128
Appears in Departments:Institute of Technology

Files in This Item:
File Description SizeFormat 
10. chapter-1.pdfAttached File356.89 kBAdobe PDFView/Open
11. chapter-2.pdf619.1 kBAdobe PDFView/Open
12. chapter-3.pdf129.45 kBAdobe PDFView/Open
13. chapter-4.pdf847.56 kBAdobe PDFView/Open
15. chapter-6.pdf739.43 kBAdobe PDFView/Open
16. chapter-7.pdf551.77 kBAdobe PDFView/Open
17. chapter-8.pdf1.11 MBAdobe PDFView/Open
18. chapter-9.pdf128.98 kBAdobe PDFView/Open
19. summary.pdf68.48 kBAdobe PDFView/Open
1. title page.pdf151.1 kBAdobe PDFView/Open
20. bibliography.pdf269.69 kBAdobe PDFView/Open
2. certificate.pdf57.88 kBAdobe PDFView/Open
3.abstract.pdf50.65 kBAdobe PDFView/Open
4. declaration.pdf53.53 kBAdobe PDFView/Open
5. acknowledgements.pdf101.39 kBAdobe PDFView/Open
6. contents.pdf52.97 kBAdobe PDFView/Open
7. list of tables.pdf53.89 kBAdobe PDFView/Open
80_recommendation.pdf166.42 kBAdobe PDFView/Open
8. list of figure.pdf51.85 kBAdobe PDFView/Open
9. abbreviations.pdf119.68 kBAdobe PDFView/Open
Show full item record


Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).

Altmetric Badge: